WuXi AppTec, Schrödinger launch ‘virtual global collaboration’ as part of drug discovery tie-up
The contract research organization (CRO) WuXi AppTec has teamed up with Schrödinger, a company that provides molecular simulations and enterprise software solutions to accelerate drug discovery and materials design.
“This is truly a new launch, so there’s no fixed head count at the moment,” Shi-Yi Liu, senior vice president, corporate communications at Schrodinger told us.
Faxian Therapeutics will be headquartered in New York City though the workforce will be global.
“WuXi has a worldwide presence, as does Schrödinger, and as needed, members from each company from all around the world will work together on this collaboration, leveraging individual expertise wherever it resides,” said Liu.
The so-called “virtual global collaboration” will be facilitated by Schrödinger’s LiveDesign platform, which allows discovery team members to communicate and collaborate in real time from anywhere.
The company has not yet decided on primary indications, though Liu said it will focus on leveraging Schrödinger’s physics-based approach to drug discovery to identify targets addressing unmet needs.
“Schrodinger will focus on the target discovery, compound design and experimental design. WuXi will work on crystallization and will execute the experiments,” she added.
No financial details are being disclosed at this time.
